CA3134209A1 - Vaccin contre des cellules de l'activation immunitaire pathogene au cours d'infections - Google Patents

Vaccin contre des cellules de l'activation immunitaire pathogene au cours d'infections Download PDF

Info

Publication number
CA3134209A1
CA3134209A1 CA3134209A CA3134209A CA3134209A1 CA 3134209 A1 CA3134209 A1 CA 3134209A1 CA 3134209 A CA3134209 A CA 3134209A CA 3134209 A CA3134209 A CA 3134209A CA 3134209 A1 CA3134209 A1 CA 3134209A1
Authority
CA
Canada
Prior art keywords
cells
vaccine
ifn
interferon
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3134209A
Other languages
English (en)
Inventor
Daniel Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
21c Bio
Original Assignee
21c Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/360,876 external-priority patent/US10632186B1/en
Application filed by 21c Bio filed Critical 21c Bio
Publication of CA3134209A1 publication Critical patent/CA3134209A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La présente invention concerne une nouvelle méthode pour prévenir ou traiter une maladie infectieuse chez le patient le nécessitant. En particulier, ladite méthode comprend l'administration d'une combinaison, d'une combinaison pharmaceutique, d'un médicament ou d'un kit de parties comprenant une première partie comprenant un vaccin à base de CD8 spécifique d'au moins un antigène associé à une maladie infectieuse, optionnellement une seconde partie comprenant un agent bloquant l'interféron alpha, et une troisième partie comprenant un interféron de type III et/ou un agent stimulant la production d'interféron de type III.
CA3134209A 2019-03-21 2020-03-20 Vaccin contre des cellules de l'activation immunitaire pathogene au cours d'infections Pending CA3134209A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962821774P 2019-03-21 2019-03-21
US62/821,774 2019-03-21
US16/360,876 2019-03-21
US16/360,876 US10632186B1 (en) 2019-03-21 2019-03-21 Vaccine to pathogenic immune activation cells during infections
EP19189405.4 2019-07-31
EP19189405 2019-07-31
PCT/EP2020/057894 WO2020188111A1 (fr) 2019-03-21 2020-03-20 Vaccin contre des cellules de l'activation immunitaire pathogène au cours d'infections

Publications (1)

Publication Number Publication Date
CA3134209A1 true CA3134209A1 (fr) 2020-09-24

Family

ID=69810883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3134209A Pending CA3134209A1 (fr) 2019-03-21 2020-03-20 Vaccin contre des cellules de l'activation immunitaire pathogene au cours d'infections

Country Status (6)

Country Link
EP (1) EP3941517A1 (fr)
JP (1) JP2022526628A (fr)
CN (1) CN114025792A (fr)
AU (1) AU2020243095A1 (fr)
CA (1) CA3134209A1 (fr)
WO (1) WO2020188111A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO2011028257A1 (fr) * 2009-08-24 2011-03-10 The Trustees Of Columbia University In The City Of New York Dosage permettant de déterminer la santé de cellules t cd8+
LT3333265T (lt) 2010-05-14 2020-05-25 Oregon Health & Science University Rekombinantiniai žcmv ir rhcmv vektoriai, koduojantys heterologinį antigeną, išskirtą iš hepatito b viruso, ir jų panaudojimas
EP3173096A1 (fr) * 2011-04-06 2017-05-31 Biovaxim Limited Compositions pharmaceutiques pour prévenir et/ou traiter une maladie vih chez l'homme
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
WO2014052545A2 (fr) * 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Expansion ciblée des lymphocytes t cd8 régulateurs spécifiques du peptide qa-1 pour améliorer l'arthrite
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター
CN103480003B (zh) * 2013-09-13 2016-03-02 中国科学院广州生物医药与健康研究院 一种引发强效cd4+ t细胞免疫反应的新型hiv疫苗
EP3256595A4 (fr) * 2015-02-10 2018-09-26 Oregon Health & Science University Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+
WO2018006067A1 (fr) * 2016-07-01 2018-01-04 Loma Linda University Peptide spécifique de la glycoprotéine d'oligodendrocyte de myéline destiné au traitement ou à la prévention de la sclérose en plaques
MX2019004518A (es) 2016-10-18 2019-06-17 Univ Oregon Health & Science Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e.

Also Published As

Publication number Publication date
JP2022526628A (ja) 2022-05-25
EP3941517A1 (fr) 2022-01-26
WO2020188111A1 (fr) 2020-09-24
CN114025792A (zh) 2022-02-08
AU2020243095A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
US8197820B2 (en) HIV-1 Tat, or derivatives thereof for prophylactic and therapeutic vaccination
US20240091340A1 (en) Pre-immunization and immunotherapy
JP2019525914A (ja) Ｈｉｖ予備免疫化および免疫療法
EP2700708B1 (fr) Amélioration de la capacité stimulatrice des lymphocytes T d'antigène humain présentant des cellules in vitro et in vivo et leur utilisation dans les vaccins
EP3460052B1 (fr) Cellules dendritiques allogéniques améliorées destinées à être utilisées dans le traitement du cancer
US20190381158A1 (en) Cell-based vaccine compositions and methods of use
TW202200784A (zh) Sars-cov2特異性t細胞組合物及其於治療及預防冠狀病毒及其他呼吸道病毒感染之用途
US10632186B1 (en) Vaccine to pathogenic immune activation cells during infections
US11957748B2 (en) Vaccine to pathogenic immune activation cells during infections
CN111849905A (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
CA3134209A1 (fr) Vaccin contre des cellules de l'activation immunitaire pathogene au cours d'infections
JP2023533613A (ja) Ｉｌ－１０を発現する複数ドナーｃｄ４＋ｔ細胞及びその使用
EP3478073A1 (fr) Compositions et procédés d'activation de cellules présentatrices d'antigène avec un poliovirus chimérique
WO2016180852A1 (fr) Procédés de préparation de cellules t spécifiques de l'antigène à partir d'un échantillon de sang de cordon ombilical
US11980663B2 (en) HIV pre-immunization and immunotherapy
WO2023238125A1 (fr) Récepteurs de lymphocytes t recombinés spécifiques d'un virus et lymphocytes t les contenant
CA3226957A1 (fr) Procedes de developpement de cellules cd3+ cd8+ contre de multiples epitopes viraux pour le traitement d'infections virales notamment de variants evoluant pour echapper a l'immunite precedent
Xie et al. Nucleofection of a DNA vaccine into human monocyte-derived dendritic cells
Schierer Modulation of dendritic cell biology by oncolytic adenoviruses and by melanoma cells lysed by oncolytic adenoviruses
Small Interfering DC2007: 5th International meeting on dendritic cell vaccination and other strategies to tip the balance of the immune system, 16–18 July, 2007, Bamberg, Germany
Engelmayer Towards the development of effective anti-HIV vaccines: Interaction and presentation of poxviruses by dendritic cells